RxDoctor Payments Data

Steven Shoemaker, MD

Interventional Cardiology · North Venice, FLNPI 1114021144

Payments from drug & device makers

$8,201in general payments, 2019–2025

Across 319 payments — averaging $25.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$1K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$608
  • Abiomed$595
  • Johnson & Johnson$530
  • Abbott$431
  • Novo Nordisk$403
  • plus $4K from 42 others

What the payments were for

  • Food & beverage$8,180100%
  • Education$220%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,201 in reported general payments places this provider in the 45th percentile of 623 interventional cardiology providers in Florida.

See all interventional cardiology providers in Florida

Medicare billing

Part B allowed, 2024
$794,750
Medicare patients
4,397
Services billed
12,766

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban696$948,905
VyndaqelTafamidis Meglumine14$469,335
XareltoRivaroxaban337$415,426
EntrestoSacubitril/Valsartan171$275,295
FarxigaDapagliflozin Propanediol197$221,695
JardianceEmpagliflozin87$131,671
Repatha SureclickEvolocumab92$85,018
BrilintaTicagrelor73$76,718
OzempicSemaglutide35$66,544
MultaqDronedarone Hcl30$40,965
VascepaIcosapent Ethyl56$30,170
Repatha SyringeEvolocumab24$27,862
Metoprolol Succinate1,299$16,907
Atorvastatin Calcium1,322$12,140
Rosuvastatin Calcium723$9,906

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Vyndaqel$208$1,418,240710 claims
Johnson & JohnsonXarelto$530$415,426337 claims
AstraZenecaFarxiga, Brilinta$313$298,414270 claims
NovartisEntresto$202$275,295171 claims
Boehringer IngelheimJardiance$115$131,67187 claims
Novo NordiskOzempic$403$66,54435 claims
Sanofi-aventis U.S. LLCMultaq$163$40,96530 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 623 interventional cardiology providers in Florida.

Other interventional cardiology in North Venice

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →